Relationships with debuts

New listing of SDS OPTIC S.A. on NewConnect

The company SDS OPTIC S.A. was newly listed on NewConnect on 15 March 2022.

SDS OPTIC S.A. is the 383^rd company listed on NewConnect and the fifth new listing on NewConnect in 2022. 

Key information

*at the proposed reference price equal to PLN 10.00

History/Business

The Issuer was established as a result of the transformation of SDS Optic Spółka z ograniczoną odpowiedzialnością, a limited liability company registered in 2013. The transformation of SDS Optic Sp. z o.o. into a joint-stock company took place in accordance with the resolution of the AGM of SDS Optic Sp. z o.o. of 10 January 2019. As a result of the transformation, SDS Optic S.A. was entered into the Register of Entrepreneurs of the National Court Register on 17 May 2019.

Its legal predecessor in 2013 was active in the field of innovative fibre optic encapsulation technology with potential application in the detection of hazardous gases and bio-chemical materials at great depths (mines). Due to the crisis in the mining industry, the Company decided to direct its activities towards medical applications.

SDS Optic S.A. works on the development of ground-breaking medical technologies at the interface and combination of optical fibre optoelectronics (photonics), molecular biology, immunochemistry and modern medical bioengineering techniques. The Company designs, develops and intends to commercialise breakthrough diagnostic and monitoring devices which support the daily work of medical personnel around the world. The Company’s vision is to help increase survival rates from cancer and other chronic diseases by 30% by 2030 and to co-create the future of breakthrough health technologies.

The Company’s key technology is a breakthrough fibre-optic micrometre probe; in combination with molecular biology, chemistry and medical bioengineering, it constitutes a globally unique biosensor, capable of taking biological measurements of living tissue in the patient’s body (in vivo testing) at a very high level of sensitivity and specificity. The Company’s technology detects the concentration of a tested substance in the body, including cancer markers, with high precision, through the identification of biomarkers using a laser beam with a specific wave as well as innovative biological components. The process lasting several minutes closes with an interpretation of a reading on the detector with an appropriate conversion algorithm in the form of a numerical result which indicates the concentration of the tested active biological compound (e.g., tumour marker). The fibre-optic microprobe technology will be commercialised under the inPROBE brand with a dedicated logo.

Throughout its history (including its legal predecessor), the Company has raised over PLN 43 million for the implementation of its projects, including contributions from both private investors, such as seed and venture capital funds, and funding under public grants, including the largest grant in the history of Polish SMEs from the European Commission under the SME Instrument Horizon 2020 programme at almost EUR 4 million. The Company is constantly expanding the pool of its employees and associates by establishing cooperation with specialists in order to ensure further growth and improve research and manufacturing processes.

As at the date of this Information Document, the Issuer’s staff numbered 28.

The share capital of the Company amounts to PLN 5,326,250 and is divided into 5,326,250 shares with a nominal value of PLN 1 each, including:

• 3,843,000 series A ordinary bearer shares,
• 83,250 series B ordinary bearer shares,
• 300,000 series C ordinary bearer shares,
• 1,100,000 series D ordinary bearer shares.

Public offering of series D shares

Public offering addressed to qualified investors or to investors each of whom acquires shares with an aggregate value in excess of EUR 100,000 in a number not exceeding 149 persons.

Legal basis: AGM Resolution of 25 May 2021

Number of issued shares: 1- 1,100,000

Number of acquired shares: 1,100,000

Issue price: PLN 10

Issue amount:  PLN 11,000,000

Number of shareholders: The shares were allotted to 26 investors who are unrelated parties including 21 individuals and 5 legal persons.

Payment: in cash

The Issuer raised a total of PLN 11,000,000 from the issue of the Series D Shares.

Selected financials (PLN):

Shareholders

A total of 3,951,750 shares, i.e., 74.19% of all shares, are subject to lock-up agreements in force for a period of 12 months (1,301,335 shares) and 18 months (2,650,415 shares) from the date of new listing on GPW.

Financial instruments newly listed on NewConnect:

• 3,843,000 series A ordinary bearer shares,
• 83,250 series B ordinary bearer shares,
• 1,100,000 series D ordinary bearer shares.